What is it? Why is it important?

For an evaluation of the study's safety and efficacy during study conduct, the SP-INV implements the planned Interim Analyses (IA).  IAs are performed as described in the study protocol and, if applicable, the Statistical Analysis Plan (SAP).

 

Results of the IA are usually provided to a Data Safety Monitoring Committee (DSMC) also named an Independent Data Monitoring Committee (IDMC). The committee advises the SP-INV on how to proceed with the study.

 

Note: The introduction of not-planned IAs or the omission of a planned IA, requires a protocol amendment. An amendment must be approved by the Ethics Committee (EC) and, if applicable, RA (e.g. Swissmedic for risk-category B and C studies).

What do I need to do?

As a SP-INV:

  • Ensure that the IA/AIs are performed as specified in the study protocol or Statistical Analysis Plan (SAP)
  • Ensure that the results are provided to the designated body (e.g. IDMC) Perform the IA(s) as described in the study protocol or SAP. In the event of a blinded study
  • Obtain recommendations from the designated body (e.g. the IDMC) and make an informed decision on how to proceed with the study

 

Decisions may include to:

  • Continue the study as planned
  • Continue the study with needed modifications (e.g. changes to the study's inclusion/exclusion criteria or sample size adjustments)
  • Temporarily suspend participant enrolment pending further recommendations from relevant bodies (e.g. DSMC/IDMC, swissethics (EC), Swissmedic, or the marketing authorisation holder)
  • Terminate the study early

Where can I get help?

Your local Research Support Centre↧ can assist you with experienced staff regarding this topic

  • Basel, Departement Klinische Forschung (DKF), dkf.unibas.ch

  • Lugano, Clinical Trials Unit (CTU-EOC), ctueoc.ch

  • Bern, Department of Clinical Research (DCR), dcr.unibe.ch

  • Geneva, Clinical Research Center (CRC), crc.hug.ch

  • Lausanne, Clinical Research Center (CRC), chuv.ch

  • St. Gallen, Clinical Trials Unit (CTU), h-och.ch

  • Zürich, Clinical Trials Center (CTC), usz.ch

SCTO Research Tools & Resources

References

CH GCP E6(R3) – see in particular 

  • Glossary: Definition interim clinical trial
  • Essential records table: Interim and final clinical reports
  • 3.16.1p,q Data handling and data analysis
  • 3.16.2a Study report
  • B10.1 Statistical considerations
  • C.3s Essentiality of trials records

ICH Topic E9 – see in particular

  • 4 Trial conduct considerations
  • 4.1 Trial monitoring and interim analysis
  • 4.2 Changes in inclusion and exclusion criteria
  • Sample size adjustments
  • 4.5 Interim Analysis and early stopping
  • 4.6 Role of IDMC
  • 7.1 Evaluation and reporting

ICH Topic E8(R1) General considerations for clinical studies - see in particular

  • 6.1.4 Access to interim data

Swiss Law

ClinO – see in particular article

  • Art. 2b Definition of intervention

ClinO-MD – see in particular article

  • Art. 2a Definition of clinical intervention
  • Art. 2a Definition of performance study

HRO – see in particular article

  • Art. 3a Definition of research
Abbreviations
  • ClinO – Clinical Trials Ordinance
  • ClinO-MD – Ordinance on Clinical Trials of Medical Devices
  • DSMC – Data Safety Monitoring Committee
  • HRO – Human Research Ordinance
  • IA – Interim Analysis
  • ICH – International Council for Harmonisation
  • ICH-GCP – International Council for Harmonisation — Good Clinical Practice
  • IDMC – Independent Data Monitoring Committee
  • SAP – Statistical Analysis Plan
  • SP-INV – Sponsor Investigator
Conduct ↦ Statistic Methodology ↦ Safety and Efficacy Evaluation ↦ Procedures
Study
Basic

Provides some background knowledge and basic definitions

Basic Monitoring
Concept

Starts with a study idea

Ends after having assessed and evaluated study feasibility

Concept Statistic Methodology
Concept Drug or Device
Development

Starts with confidence that the study is feasible

Ends after having received ethics and regulatory approval

Development Drug or Device
Set-Up

Starts with ethics and regulatory approval

Ends after successful study initiation

Set-Up Ethics and Laws
Set-Up Statistic Methodology
Set-Up Quality and Risk
Set-Up Drug or Device
Conduct

Starts with participant recruitment

Ends after the last participant has completed the last study visit

Conduct Drug or Device
Completion

Starts with last study visit completed

Ends after study publication and archiving

Completion Drug or Device
Current Path (click to copy): Conduct ↦ Statistic Methodology ↦ Safety and Efficacy Evaluation ↦ Procedures